OmniSeq News

OmniSeq Names Dr. Shengle Zhang as New Lab Director

FOR IMMEDIATE RELEASE MEDIA CONTACT: Sawyer Lipari Lambert & Co. 313.309.9551 slipari@lambert.com OmniSeq Names Dr. Shengle Zhang as New Lab Director Fast-growing cancer diagnostic laboratory continues focus on development of innovative product breakthroughs...

Schoenborn named CEO at OmniSeq

June 26, 2019 Buffalo News - OmniSeq Inc., a molecular diagnostic laboratory on the Buffalo Niagara Medical Campus, has a new CEO. Margot P. Schoenborn, formerly the company's chief administrative officer, has been promoted to the position.

People in the News

June 26, 2019 GenomeWeb - OmniSeq announced today that it has appointed Margot Schoenborn to succeed Mark Gardner as the firm's CEO.

Margot Schoenborn becomes CEO of fast-growing OmniSeq

Business First - Margot Schoenborn has quite the resume. Now she gets to add yet another interesting professional experience: biotech boss. Schoenborn has been named the CEO of OmniSeq, which develops and sells molecular diagnostic tests that show cancer patients what...

OmniSeq & LabCorp Launch OmniSeq Advance℠ Assay

New test combines both targeted therapy and immune-oncology biomarkers in a single test with 99% actionability, providing benefits for the treatment of patients and the development of new therapies.ASCO, CHICAGO, ILLINOIS – June 1, 2018 – OmniSeq® , a CAP accredited,...

Follow Us on Twitter

Congrats to everyone at @OmniSeq on this @PLOS ONE publication! Using more than 700 FFPE tumor specimens, OmniSeq validated the performance of the @illumina's TSO500 assay, an integral component OmniSeq INSIGHT https://tinyurl.com/3ummv3dd
@Labcorp #oncology

Come join us @sitcancer (SITC 21), poster 77. Learn how @OmniSeq looks beyond PD-L1, TMB and MSI and investigates the prevalence of secondary immunotherapeutic targets to provide additional therapeutic options for patients. #oncology #PrecisionMedicine
https://jitc.bmj.com/content/9/Suppl_2/A86

Cancer of unknown primary (CUP) is a rare tumor type and identifying new targets for immunotherapeutic opportunities in this patient group is a critical. Join us at @sitcancer (SITC 21) and learn how @OmniSeq addresses this unmet need.
Visit poster #70: https://jitc.bmj.com/content/9/Suppl_2/A78

Come join us at @sitcancer 2021 and learn more about continued immunotherapy biomarker innovation led by @OmniSeq. We reveal our latest discovery of Cancer Testis Antigen Burden: A novel predictive biomarker for response to immunotherapy in solid tumors.
https://jitc.bmj.com/content/9/Suppl_2/A89

Congrats to @OmniSeq's Jeffrey Conroy and @PablaSabi on their contribution to the TMB Harmonization Consortium's study aimed at facilitating harmonization and alignment across tissue TMB assays.
#precisiononcology
@Labcorp
@LabcorpDrugDev
https://tinyurl.com/7p7mkvkz

Load More...